-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XBH-25 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XBH-25 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XBH-25 in Solid Tumor Drug Details: XHB-25 is under development for...
-
Sector Analysis
Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Ovarian Cancer Market Report Overview The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan. Ovarian cancer is one of the most lethal gynecological cancers worldwide. Approximately 90% of ovarian cancer cases are epithelial, with distinct sites of origin arising from the ovarian surface epithelium or distal fallopian...
-
Product Insights
Malignant Pleural Effusion – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Pleural Effusion - Drugs In Development, 2023’, provides an overview of the Malignant Pleural Effusion pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pleural Effusion – Drugs In Development, 2023
Global Markets Direct’s, ‘Pleural Effusion - Drugs In Development, 2023’, provides an overview of the Pleural Effusion pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pleural Effusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Pleural Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Pleural Disease - Drugs In Development, 2023’, provides an overview of the Pleural Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pleural Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Anaplastic Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Anaplastic Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Anaplastic Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Malignant Pleural Mesothelioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Pleural Mesothelioma - Drugs In Development, 2023’, provides an overview of the Malignant Pleural Mesothelioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olvimulogene Nanivacirepvec in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olvimulogene Nanivacirepvec in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene Nanivacirepvec in Ovarian Cancer Drug Details: Olvimulogene nanivacirepvec (GL-ONC1)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olvimulogene Nanivacirepvec in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olvimulogene Nanivacirepvec in Head And Neck Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene Nanivacirepvec in Head And Neck Cancer Drug...